Date: 2013-06-05
Type of information: Development agreement
Compound: Dymista® and future product development
Company: Meda (Sweden) Cipla (India)
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Type agreement: development
commercialisation
Action mechanism:
Disease: allergic rhinitis
Details: * On June 5, 2013, Meda has announced that the company is broadening its collaboration with the Indian pharmaceutical company Cipla, thereby expanding its exclusive rights to Dymista® and future product development. Through the extended partnership, Meda now have full coverage in all growth markets in Latin- and South America, Middle East and Africa and Asia, including more than 120 new markets.
Meda and Cipla will cooperate on product development of Dymista®. Cipla will be responsible for formulation, while Meda will be responsible for clinical development, registration, marketing and sales. The companies will also collaborate on future production of Dymista® and any new products developed.
allergic rhinitis. The efficacy and safety of Dymista has been documented in several studies with more than 4,000 patients, including a long-term safety study with more than 600 patients. Dymista has consistently shown faster and more complete symptom relief than standard treatment in the US. Dymista® was approved in the US in May 2012 and in Europe in January 2013.
Financial terms:
Latest news:
